![Voir la vidéo](squelettes/img/bt-ytb-1.png)
Events
On 2 April, Delpharm finalized the acquisition of the Meppel pharmaceutical manufacturing facility, from Astellas in the Netherlands.
The acquisition of this site, fully equipped with state-of-the-art technologies, will be an additional asset to the production of solid dosage forms. With FDA certification, Delpharm has strengthened its position as a supplier to the US market.
A leading CDMO
Drug developer and Contract manufacturer. With its plants network, Delpharm is in the Top 5 CDMOs Worldwide.
Dosage forms
Delpharm produces most dosage forms; non-sterile and sterile liquids, solids, semi-solids and biotech.
Development & Regulation
A team of experts to support new pharmaceutical products.
![100](local/cache-vignettes/L100xH100/arton581-51857.png?1683209648)
100
Management ownership 100%
![1](local/cache-vignettes/L100xH100/arton582-5a9dc.png?1683209648)
1
Turnover billion €
![5](local/cache-vignettes/L100xH100/arton583-ab3f2.png?1683209648)
5
World Top 5
![6000](local/cache-vignettes/L100xH100/arton584-a2204.png?1683209648)
6000
Headcount
![](local/cache-vignettes/L600xH338/rubon93-5447d.jpg?1683209649)
News
A new state of the art technology to better understand your drug substance and drug product is now available at Delpharm Development Leiden
Prefilled syringes
With Delpharm Leiden development center and Tours experts, we can support you in the development and manufacture of prefilled syringes. We have the capacity to produce between 25 and 30 million syringes a year in sizes ranging from 1ml to 50ml.Regulatory affairs
A full team dedicated to support you in the long term or for emergency needs.Read more...
Customer references
![Biocodex](local/cache-gd2/e2/88029ae1e925cb1b3060b38ba36cd5.jpg?1683208965)
![Cooper](local/cache-gd2/2f/681b56fe5966854f6c083e24a772dd.jpg?1683208965)
![Novartis](local/cache-gd2/12/24a0fb19d99c8d92d59ed336556e00.jpg?1683208964)
![Zoetis](local/cache-gd2/f7/6a3ddf5d3c9d93cb37c3dbc2021e88.jpg?1683208965)
![Aurobindo](local/cache-gd2/c8/9b22c1dce98ca539fec1be0e7120e7.jpg?1683208965)
![HRA Pharma](local/cache-gd2/15/2d5db874a06e75f2307a50a76197d7.jpg?1683208965)
![Zentiva](local/cache-gd2/39/dd284245f24203fe0d370d8d3d97c9.jpg?1683208965)
![LFB](local/cache-gd2/41/e9a800f08f1402c8fcd3875acb47a0.jpg?1683208965)
![Aguettant](local/cache-gd2/8e/d34711e4c8d62638c8270de17b2265.jpg?1683208966)
![GlaxoSmithKline](local/cache-gd2/02/e6f9a8b6365a05bd8d26f765b7bea7.jpg?1683208966)
![Merck](local/cache-gd2/a6/8a7cea4833316663a436dc90fda6f5.jpg?1683208964)
![Sanofi](local/cache-gd2/bd/73b71ad156e377da6d125dd0f398b8.jpg?1683208965)
![Biogaran](local/cache-gd2/26/a7b753e445733462b9600de504355d.jpg?1683208964)
![Eisai](local/cache-gd2/c7/dee504f7dc241b8cf3e09cc0d4177f.jpg?1683208966)
![OM Pharma](local/cache-gd2/4e/8a7de29298afe709f8d957e0ca7948.jpg?1683208965)
![Meda](local/cache-gd2/ce/f30f8863988a5be9e2ac59e92a5d66.jpg?1683208965)
![Mylan](local/cache-gd2/f9/84b9d3c167c8f1f975c1e83b3c7b72.png?1683208965)
![Urgo](local/cache-gd2/60/acb874376da4ea4772081b86b5efde.jpg?1683208965)
![Bayer](local/cache-gd2/e2/ac8592cb5686607c6c2dcc177b7fcb.jpg?1683208965)
![Genfit](local/cache-gd2/b7/998e0fd8d7c537801f8e3da63a83ab.jpg?1683208965)
![](local/cache-gd2/e2/1fd09f37237d36de5079a49d0eacae.png?1683209649)
![Boehringer Indelheim](local/cache-gd2/a8/c7f0573ca48e888e755595f9f79c98.jpg?1683208965)
![Servier](local/cache-gd2/70/59106a84e41269f784431cec10115f.jpg?1683208964)
![Sanionia](local/cache-gd2/b8/f6dcf11667c15e2dada075d4b11be0.jpg?1683208965)
![](local/cache-gd2/e3/ed70617050cdadd5e753409420cf84.jpg?1683209649)
![Teva](local/cache-gd2/6d/266474814f512c4bbac4826d1b42e6.png?1683208964)
![Bracco](local/cache-gd2/17/c79b291cb25e3414fe49fabe7ca1dd.jpg?1683208965)
![Takeda](local/cache-gd2/a7/1d7c06c2dd6bf5e101f573d4f3374d.jpg?1683208965)
![Daiichi-Sankyo](local/cache-gd2/fa/f0e6cedeedcab9f0e47a1238beaf02.jpg?1683208965)
![Sandoz](local/cache-gd2/41/59aee8874b563a4f44591e1a001903.jpg?1683208965)